The number of targeted therapies available for the treatment of different cancers increases annually. However, for many of these agents, we do not have effective predictive biomarkers. The result is that patients who might benefit for certain therapies are not receiving them, and patients receive therapies from which they receive no benefit. In many cases, it is likely that an individual drug might be effective in only a small subset of a particular cancer, so that without a validated predictive biomarker, introduction to that cancer is impossible. W propose a novel and generalizable functional predictive biomarker approach, based on measuring death signaling early in the response to targeted therapies. We hypothesize that if we could identify those cancer cells that induce the strongest activation ofthe mitochondrial apoptotic pathway at early time points in response to a drug, we could thus identify those tumors that are most likely to respond in vivo. We are greatly assisted in this approach by our development of a novel tool, BH3 profiling, which can measure a cell's proximity to the threshold of apoptosis. Our approach is to treat cells with drugs, measure at short time points the extent to which apoptotic signaling is forcing cells toward the threshold of apoptosis, a method we call Dynamic BH3 Profiling. As we will show, we are now adept at making such measurements. Moreover, we already have exciting preliminary data that suggests that those cells that are pushed the most are also those that are destined to choose death as a cell fate. We propose to develop Dynamic BH3 profling first in AML cell lines, and then in murine AML primagrafts. Our output will be a set of drugs for which we have validated Dynamic BH3 profiling as a predicitve biomarker in vivo. These drugs might be useful as single agents, or as agents to increase priming to enhance sensitiity to conventional, curative agents. Acute myelogenous leukemia (AML) is an attractive disease in which to test our ideas because of our established expertise, established relationships, and access to clinical samples. Dynamic BH3 profling has the potential to expand the pharmacopeia and personalize therapeutic decision making for the AML patient.

Public Health Relevance

The number of Innovative targeted therapies for cancer is increasing. However, oncologists still do not have the information they need to make sure that individual cancer patients are being matched with the targeted therapies that best meet their needs. In this application we propose a novel approach, dynamic BH3 profling, to personalizing cancer therapy by measuring changes in cancer cells induced by targeted therapies.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-C (J1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Brigham and Women's Hospital
United States
Zip Code
Townsend, Elizabeth C; Murakami, Mark A; Christodoulou, Alexandra et al. (2016) The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell 29:574-86
Arreba-Tutusaus, P; Mack, T S; Bullinger, L et al. (2016) Impact of FLT3-ITD location on sensitivity to TKI-therapy in vitro and in vivo. Leukemia 30:1220-5
Tanaka, Minoru; Roberts, Justin M; Seo, Hyuk-Soo et al. (2016) Design and characterization of bivalent BET inhibitors. Nat Chem Biol 12:1089-1096
Wu, H; Hu, C; Wang, A et al. (2016) Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia. Leukemia 30:173-81
Wu, H; Hu, C; Wang, A et al. (2016) Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML. Leukemia 30:754-7
Puram, Rishi V; Kowalczyk, Monika S; de Boer, Carl G et al. (2016) Core Circadian Clock Genes Regulate Leukemia Stem Cells in AML. Cell 165:303-16
Brien, Gerard L; Valerio, Daria G; Armstrong, Scott A (2016) Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs. Cancer Cell 29:464-76
Zhu, Nan; Chen, Mo; Eng, Rowena et al. (2016) MLL-AF9- and HOXA9-mediated acute myeloid leukemia stem cell self-renewal requires JMJD1C. J Clin Invest 126:997-1011
Schneider, Rebekka K; Schenone, Monica; Ferreira, Monica Ventura et al. (2016) Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9. Nat Med 22:288-97
Hatcher, John M; Weisberg, Ellen; Sim, Taebo et al. (2016) Discovery of a Highly Potent and Selective Indenoindolone Type 1 Pan-FLT3 Inhibitor. ACS Med Chem Lett 7:476-81

Showing the most recent 10 out of 280 publications